{"id":31019,"date":"2025-07-10T12:25:20","date_gmt":"2025-07-10T02:25:20","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=31019"},"modified":"2025-07-17T12:55:04","modified_gmt":"2025-07-17T02:55:04","slug":"ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/","title":{"rendered":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies"},"content":{"rendered":"\n<p>In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX&#8217;s lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into the company&#8217;s strategic pathway, including FDA fast track designation and potential market opportunities exceeding $1.8 billion. Learn how PTX&#8217;s targeted Ras pathway disruption could unlock new treatments for multiple cancers like lung, pancreatic, and biliary tumours. The conversation also covers funding strategies, the impact of government R&amp;D incentives, and upcoming milestones that could accelerate PTX\u2019s journey to market. Whether you&#8217;re an early stage biotech investor or interested in innovative cancer therapies, this interview provides valuable insights into PTX\u2019s potential to revolutionise oncology care.<\/p>\n\n\n\n<p><strong>Watch the full interview below.<\/strong><\/p>\n\n\n\n<div class=\"yt-container\"><iframe loading=\"lazy\" width=\"100%\" height=\"400\" src=\"https:\/\/www.youtube.com\/embed\/1HNy14KOnUg\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX&#8217;s lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into [&hellip;]<\/p>\n","protected":false},"author":38,"featured_media":31020,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[17],"class_list":["post-31019","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-small-caps"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics\" \/>\n<meta property=\"og:description\" content=\"In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX&#8217;s lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T02:25:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-17T02:55:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png\" \/>\n\t<meta property=\"og:image:width\" content=\"549\" \/>\n\t<meta property=\"og:image:height\" content=\"308\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Adrian Montesano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adrian Montesano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\"},\"author\":{\"name\":\"Adrian Montesano\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"headline\":\"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies\",\"datePublished\":\"2025-07-10T02:25:20+00:00\",\"dateModified\":\"2025-07-17T02:55:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\"},\"wordCount\":156,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png\",\"keywords\":[\"Small Caps\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\",\"name\":\"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png\",\"datePublished\":\"2025-07-10T02:25:20+00:00\",\"dateModified\":\"2025-07-17T02:55:04+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png\",\"width\":549,\"height\":308},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6\",\"name\":\"Adrian Montesano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g\",\"caption\":\"Adrian Montesano\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics","og_description":"In this exclusive interview, Jess Fertig hosts James McDonnell, CEO of Prescient Therapeutics (ASX: PTX), a biotech innovator in the healthcare sector. Discover how PTX&#8217;s lead asset, PTX 100, is advancing through crucial Phase 2 trials targeting cutaneous T cell lymphoma (CTCL), with promising response rates and minimal serious adverse events. James shares insights into [&hellip;]","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/","og_site_name":"PTX Therapeutics","article_published_time":"2025-07-10T02:25:20+00:00","article_modified_time":"2025-07-17T02:55:04+00:00","og_image":[{"width":549,"height":308,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png","type":"image\/png"}],"author":"Adrian Montesano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Adrian Montesano","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/"},"author":{"name":"Adrian Montesano","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"headline":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies","datePublished":"2025-07-10T02:25:20+00:00","dateModified":"2025-07-17T02:55:04+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/"},"wordCount":156,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png","keywords":["Small Caps"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/","name":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png","datePublished":"2025-07-10T02:25:20+00:00","dateModified":"2025-07-17T02:55:04+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/07\/Screenshot-2025-07-17-121700.png","width":549,"height":308},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/ptx-asx-groundbreaking-phase-2-progress-unlocking-cancer-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"PTX.ASX: Groundbreaking Phase 2 Progress | Unlocking Cancer Therapies"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/77eeea3f70b4075df3b2207ba88cc5b6","name":"Adrian Montesano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d23955e73043fde98cb92bd29b69f088f6103da014084b9f3e2fffa65e5558ea?s=96&d=mm&r=g","caption":"Adrian Montesano"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/adrian-montesano\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/31019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=31019"}],"version-history":[{"count":4,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/31019\/revisions"}],"predecessor-version":[{"id":31032,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/31019\/revisions\/31032"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/31020"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=31019"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=31019"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=31019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}